Last month, the US Food and Drug Administration (FDA) published final guidance designed to help sponsors identify appropriate supplement categories for biosimilar prior approval supplements. The guidance establishes six distinct categories and outlines the agency's review goals for each, fulfilling a commitment made in the Biosimilar User Fee Amendments of 2022 (BsUFA III) commitment letter. […]